Angiodynamics Inc (ANGO) Stock Price & Analysis
Angiodynamics Inc (ANGO) rose 1.12% to USD 13.59 as of July 25, 2026 at 13:06 UTC, according to Nexqual real-time market data.
ANGO last closed at USD 13.44; the session ranged USD 13.42–13.76 on volume of 314,788 shares. Market capitalization is $561.71M, with a 52-week range of USD 8.36–15.2 (NMS). Source: Nexqual, July 25, 2026 at 13:06 UTC.
Key Statistics (as of July 25, 2026 at 13:06 UTC)
| Price | USD 13.59 |
|---|---|
| Change | ▲ 1.12% (up) |
| Previous Close | USD 13.44 |
| Open | USD 13.56 |
| Day Range | USD 13.42 – 13.76 |
| 52-Week Range | USD 8.36 – 15.2 |
| Volume | 314,788 shares |
| Market Cap | $561.71M |
| Exchange | NMS |
Technical Analysis (ANGO)
Nexqual's technical model rates ANGO "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 13:06 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.79 (neutral) |
| vs SMA50 | Above (USD 12.44) |
| MACD | 0.38 (positive) |
Analyst Ratings (ANGO)
Wall Street analysts rate ANGO "Strong Buy" based on 4 analysts, with a mean price target of USD 20 (range USD 17–24), per Nexqual as of July 25, 2026 at 13:06 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 20 |
| High Target | USD 24 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (ANGO)
| Next Earnings Date | 2026-10-01 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $80.50M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-05-31 | USD -0.07 vs est -0.09 ▲ beat |
| 2026-02-28 | USD 0.02 vs est -0.11 ▲ beat |
| 2025-11-30 | USD 0 vs est -0.1 ▲ beat |
| 2025-08-31 | USD -0.1 vs est -0.12 ▲ beat |
Source: Nexqual, July 25, 2026 at 13:06 UTC.
Financials & Fundamentals (ANGO)
| Total Revenue | $320.17M |
|---|---|
| Revenue Growth (YoY) | +8.00% |
| Gross Margin | +54.62% |
| Operating Margin | -6.52% |
| Profit Margin | -11.48% |
| ROE | -20.77% |
| Debt / Equity | 6.41 |
| Current Ratio | 2.19 |
| Total Cash | $53.86M |
| Total Debt | $10.96M |
| Free Cash Flow | $21.77M |
Source: Nexqual, July 25, 2026 at 13:06 UTC.
Financial Health Score (ANGO)
Nexqual rates Angiodynamics Inc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 13:06 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 55%, operating -7% |
| Balance Sheet | Strong — $54M cash vs $11M debt, net cash position |
| Cash Flow | Solid — FCF $22M, 7% margin |
| Efficiency | Critical — ROE -21%, ROA -5.1% |
Ownership (ANGO)
| Insider Ownership | +12.52% |
|---|---|
| Institutional Ownership | +94.57% |
| Shares Outstanding | 41.33M |
| Float | 31.86M |
| Short % of Float | +3.39% |
Source: Nexqual, July 25, 2026 at 13:06 UTC.
Leadership (ANGO)
Angiodynamics Inc is led by James C. Clemmer (age 61), CEO, President & Director, per Nexqual as of July 25, 2026 at 13:06 UTC.
| CEO, President & Director | James C. Clemmer (age 61) |
|---|---|
| Executive VP & CFO | Stephen A. Trowbridge (age 51) |
| Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | Warren G. Nighan (age 56) |
| Vice President of Communications | Saleem M. Cheeks |
| Senior Vice President of Business Development & Strategy | Benjamin H. Davis (age 61) |
Major Backers & Investors (ANGO)
Notable institutional backers of Angiodynamics Inc include Point72 Asset Management, L.P., Systematic Financial Management, L.P., Broadfin Holdings LLC, according to Nexqual as of July 25, 2026 at 13:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Point72 Asset Management, L.P. | 7.7% |
| Systematic Financial Management, L.P. | 5.94% |
| Broadfin Holdings LLC | 5.01% |
| Armistice Capital, LLC | 4.52% |
| Royce & Associates LP | 3.7% |
| Weber Capital Management LLC /ADV | 3.32% |
| Bastion Asset Management Inc. | 3.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.68% |
| Vanguard Group | 8.25% |
| State Street | 3.23% |
Source: Nexqual, July 25, 2026 at 13:06 UTC.
From Angiodynamics Inc's Latest SEC 10-K Filing (filed 2026-07-14)
Key Strengths & Strategy (as disclosed to the SEC)
- Thrombectomy Our Thrombus Management portfolio includes the AlphaVac Mechanical Thrombectomy System, AngioVac venous drainage cannula and circuit, as well as catheter directed thrombolytic devices, including the Uni-Fuse system and the Uni-Fuse+ system.
- AngioDynamics' Uni-Fuse infusion catheter features pressure response outlets, a proprietary slit technology that provides a consistent, even distribution of fluid volume along the entire length of the infusion pattern, designed to provide an advantage over standard side-hole catheters. 4 NanoKnife The NanoKnife IRE Ablation System is an alternative to traditional thermal ablation that received 510(k) clearance from the Food and Drug Administration for the surgical ablation of soft tissue.
- In December 2024, the NanoKnife System received expanded FDA 510(k) clearance for the ablation of prostate tissue which broadens treatment options for men and reinforces the system's strong safety and efficacy profile.
- The Solero MTA System and Accessories are indicated for the ablation of soft tissue during open procedures by the FDA in the USA and for open laparoscopic and percutaneous procedures under the European MDR regulations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATRC | AtriCure, Inc. | USD 35.04 | ▲ 4.53% |
| CNMD | CONMED Corporation | USD 42.68 | ▲ 1.62% |
| MMSI | Merit Medical Systems, Inc. | USD 74.32 | ▲ 1.66% |
| OFIX | Orthofix Medical Inc. | USD 11.25 | ▲ 2.09% |
| ICUI | ICU Medical, Inc. | USD 157.44 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 13:06 UTC. This page is informational and not investment advice.